As the inhibition of DTYMK and PARP1 was found to be effective in in vitro and in vivo trials in numerous malignancies due to their important function in maintaining genome stability, we suggest that the application of pamiparib together with Ymu1 may be beneficial for UM patients. This evidence concerns the gene PARP1 and cancer.